{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T13:16:51Z","timestamp":1769606211097,"version":"3.49.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T00:00:00Z","timestamp":1552262400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T00:00:00Z","timestamp":1552262400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The second-in-class proteasome inhibitor (PI) carfilzomib (Kyprolis, Cfz) has contributed to a substantial advancement in multiple myeloma treatment by improving patient survival and quality of life. A considerable portion of patients however display intrinsic resistance to Cfz. Our mechanistic understanding of intrinsic Cfz resistance is limited due to a lack of suitable cell-based models. We report that H727 human bronchial carcinoid cells are inherently resistant to Cfz, yet susceptible to other PIs and inhibitors targeting upstream components of the ubiquitin-proteasome system (UPS). These results indicate that H727 cells remain dependent on the UPS for cell survival and growth despite harboring intrinsic resistance to Cfz. Alterations in the composition of proteasome catalytic subunits via interferon-\u03b3 treatment or siRNA knockdown results in sensitization of H727 cells to Cfz. We postulate that a potential link may exist between the composition of proteasome catalytic subunits and the cellular response to Cfz. Overall, H727 cells may serve as a useful cell-based model for <jats:italic>de novo<\/jats:italic> Cfz resistance and our results suggest previously unexplored mechanisms of <jats:italic>de novo<\/jats:italic> PI resistance.<\/jats:p>","DOI":"10.1038\/s41598-019-40635-1","type":"journal-article","created":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T11:03:05Z","timestamp":1552302185000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["H727 cells are inherently resistant to the proteasome inhibitor carfilzomib, yet require proteasome activity for cell survival and growth"],"prefix":"10.1038","volume":"9","author":[{"given":"Min Jae","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Eun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Bhattarai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7805-869X","authenticated-orcid":false,"given":"Wooin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyung Bo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,11]]},"reference":[{"key":"40635_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.bbamcr.2013.08.012","volume":"1843","author":"M Schmidt","year":"2014","unstructured":"Schmidt, M. & Finley, D. Regulation of proteasome activity in health and disease. Biochim Biophys Acta 1843, 13\u201325, https:\/\/doi.org\/10.1016\/j.bbamcr.2013.08.012 (2014).","journal-title":"Biochim Biophys Acta"},{"key":"40635_CR2","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1002\/prca.201000149","volume":"5","author":"X Wang","year":"2011","unstructured":"Wang, X., Zhao, Z., Luo, Y., Chen, G. & Li, Z. Gel-based proteomics analysis of the heterogeneity of 20S proteasomes from four human pancreatic cancer cell lines. Proteomics Clin Appl 5, 484\u2013492, https:\/\/doi.org\/10.1002\/prca.201000149 (2011).","journal-title":"Proteomics Clin Appl"},{"key":"40635_CR3","doi-asserted-by":"publisher","first-page":"18599","DOI":"10.1073\/pnas.1009778107","volume":"107","author":"B Guillaume","year":"2010","unstructured":"Guillaume, B. et al. Two abundant proteasome subtypes that uniquely process some antigens presented by HLA class I molecules. Proc Natl Acad Sci USA 107, 18599\u201318604, https:\/\/doi.org\/10.1073\/pnas.1009778107 (2010).","journal-title":"Proc Natl Acad Sci USA"},{"key":"40635_CR4","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1006\/jmbi.2000.4185","volume":"303","author":"B Dahlmann","year":"2000","unstructured":"Dahlmann, B., Ruppert, T., Kuehn, L., Merforth, S. & Kloetzel, P. M. Different proteasome subtypes in a single tissue exhibit different enzymatic properties. J Mol Biol 303, 643\u2013653, https:\/\/doi.org\/10.1006\/jmbi.2000.4185 (2000).","journal-title":"J Mol Biol"},{"key":"40635_CR5","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1093\/cvr\/cvp217","volume":"85","author":"A Kloss","year":"2010","unstructured":"Kloss, A., Meiners, S., Ludwig, A. & Dahlmann, B. Multiple cardiac proteasome subtypes differ in their susceptibility to proteasome inhibitors. Cardiovasc Res 85, 367\u2013375, https:\/\/doi.org\/10.1093\/cvr\/cvp217 (2010).","journal-title":"Cardiovasc Res"},{"key":"40635_CR6","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.coi.2011.12.002","volume":"24","author":"N Vigneron","year":"2012","unstructured":"Vigneron, N. & Van den Eynde, B. J. Proteasome subtypes and the processing of tumor antigens: increasing antigenic diversity. Curr Opin Immunol 24, 84\u201391, https:\/\/doi.org\/10.1016\/j.coi.2011.12.002 (2012).","journal-title":"Curr Opin Immunol"},{"key":"40635_CR7","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1111\/j.1471-4159.2012.07699.x","volume":"121","author":"J Zheng","year":"2012","unstructured":"Zheng, J., Dasgupta, A. & Bizzozero, O. A. Changes in 20S subunit composition are largely responsible for altered proteasomal activities in experimental autoimmune encephalomyelitis. J Neurochem 121, 486\u2013494, https:\/\/doi.org\/10.1111\/j.1471-4159.2012.07699.x (2012).","journal-title":"J Neurochem"},{"key":"40635_CR8","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1002\/cbic.201600488","volume":"17","author":"K Carmony","year":"2016","unstructured":"Carmony, K., Lee, W. & Kim, K. B. High-Resolution Snapshots of Proteasome Inhibitors in Action Revise Inhibition Paradigms and Inspire Next-Generation Inhibitor Design. Chembiochem 17, 2115\u20132117, https:\/\/doi.org\/10.1002\/cbic.201600488 (2016).","journal-title":"Chembiochem"},{"key":"40635_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.chembiol.2012.01.003","volume":"19","author":"AF Kisselev","year":"2012","unstructured":"Kisselev, A. F., van der Linden, W. A. & Overkleeft, H. S. Proteasome inhibitors: an expanding army attacking a unique target. Chem Biol 19, 99\u2013115, https:\/\/doi.org\/10.1016\/j.chembiol.2012.01.003 (2012).","journal-title":"Chem Biol"},{"key":"40635_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.critrevonc.2018.02.008","volume":"125","author":"A Mushtaq","year":"2018","unstructured":"Mushtaq, A. et al. Efficacy and toxicity profile of carfilzomib based regimens for treatment of multiple myeloma: A systematic review. Crit Rev Oncol Hematol 125, 1\u201311, https:\/\/doi.org\/10.1016\/j.critrevonc.2018.02.008 (2018).","journal-title":"Crit Rev Oncol Hematol"},{"key":"40635_CR11","doi-asserted-by":"publisher","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","volume":"120","author":"DS Siegel","year":"2012","unstructured":"Siegel, D. S. et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood 120, 2817\u20132825, https:\/\/doi.org\/10.1182\/blood-2012-05-425934 (2012).","journal-title":"Blood"},{"key":"40635_CR12","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1111\/bjh.14549","volume":"177","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos, M. A. et al. Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study. Br J Haematol 177, 404\u2013413, https:\/\/doi.org\/10.1111\/bjh.14549 (2017).","journal-title":"Br J Haematol"},{"key":"40635_CR13","doi-asserted-by":"publisher","unstructured":"Goldschmidt, H. et al. Carfilzomib-dexamethasone versus subcutaneous or intravenous bortezomib in relapsed or refractory multiple myeloma: secondary analysis of the phase 3 ENDEAVOR study. Leuk Lymphoma, 1\u201311, https:\/\/doi.org\/10.1080\/10428194.2017.1376743 (2017).","DOI":"10.1080\/10428194.2017.1376743"},{"key":"40635_CR14","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","volume":"18","author":"MA Dimopoulos","year":"2017","unstructured":"Dimopoulos, M. A. et al. Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial. Lancet Oncol 18, 1327\u20131337, https:\/\/doi.org\/10.1016\/S1470-2045(17)30578-8 (2017).","journal-title":"Lancet Oncol"},{"key":"40635_CR15","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/leu.2016.176","volume":"31","author":"R Hajek","year":"2017","unstructured":"Hajek, R. et al. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia 31, 107\u2013114, https:\/\/doi.org\/10.1038\/leu.2016.176 (2017).","journal-title":"Leukemia"},{"key":"40635_CR16","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1182\/blood-2015-11-683854","volume":"127","author":"JR Berenson","year":"2016","unstructured":"Berenson, J. R. et al. CHAMPION-1: a phase 1\/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Blood 127, 3360\u20133368, https:\/\/doi.org\/10.1182\/blood-2015-11-683854 (2016).","journal-title":"Blood"},{"key":"40635_CR17","doi-asserted-by":"publisher","first-page":"23704","DOI":"10.18632\/oncotarget.25281","volume":"9","author":"C Shah","year":"2018","unstructured":"Shah, C. et al. Efficacy and safety of carfilzomib in relapsed and\/or refractory multiple myeloma: systematic review and meta-analysis of 14 trials. Oncotarget 9, 23704\u201323717, https:\/\/doi.org\/10.18632\/oncotarget.25281 (2018).","journal-title":"Oncotarget"},{"key":"40635_CR18","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1182\/blood-2014-02-556308","volume":"124","author":"N Lendvai","year":"2014","unstructured":"Lendvai, N. et al. A phase 2 single-center study of carfilzomib 56 mg\/m2 with or without low-dose dexamethasone in relapsed multiple myeloma. Blood 124, 899\u2013906, https:\/\/doi.org\/10.1182\/blood-2014-02-556308 (2014).","journal-title":"Blood"},{"key":"40635_CR19","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1182\/blood-2016-03-707596","volume":"128","author":"H Avet-Loiseau","year":"2016","unstructured":"Avet-Loiseau, H. et al. Carfilzomib significantly improves the progression-free survival of high-risk patients in multiple myeloma. Blood 128, 1174\u20131180, https:\/\/doi.org\/10.1182\/blood-2016-03-707596 (2016).","journal-title":"Blood"},{"key":"40635_CR20","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos, M. A. et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol 17, 27\u201338, https:\/\/doi.org\/10.1016\/S1470-2045(15)00464-7 (2016).","journal-title":"Lancet Oncol"},{"key":"40635_CR21","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart, A. K. et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med 372, 142\u2013152, https:\/\/doi.org\/10.1056\/NEJMoa1411321 (2015).","journal-title":"N Engl J Med"},{"key":"40635_CR22","doi-asserted-by":"publisher","first-page":"2284","DOI":"10.1182\/blood-2015-05-643320","volume":"126","author":"JJ Shah","year":"2015","unstructured":"Shah, J. J. et al. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood 126, 2284\u20132290, https:\/\/doi.org\/10.1182\/blood-2015-05-643320 (2015).","journal-title":"Blood"},{"key":"40635_CR23","doi-asserted-by":"publisher","first-page":"14814","DOI":"10.18632\/oncotarget.4530","volume":"6","author":"I Riz","year":"2015","unstructured":"Riz, I., Hawley, T. S. & Hawley, R. G. KLF4-SQSTM1\/p62-associated prosurvival autophagy contributes to carfilzomib resistance in multiple myeloma models. Oncotarget 6, 14814\u201314831, https:\/\/doi.org\/10.18632\/oncotarget.4530 (2015).","journal-title":"Oncotarget"},{"key":"40635_CR24","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1021\/mp300044b","volume":"9","author":"L Ao","year":"2012","unstructured":"Ao, L. et al. Development of peptide-based reversing agents for p-glycoprotein-mediated resistance to carfilzomib. Mol Pharm 9, 2197\u20132205, https:\/\/doi.org\/10.1021\/mp300044b (2012).","journal-title":"Mol Pharm"},{"key":"40635_CR25","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.4161\/cbt.29452","volume":"15","author":"Y Zang","year":"2014","unstructured":"Zang, Y., Kirk, C. J. & Johnson, D. E. Carfilzomib and oprozomib synergize with histone deacetylase inhibitors in head and neck squamous cell carcinoma models of acquired resistance to proteasome inhibitors. Cancer Biol Ther 15, 1142\u20131152, https:\/\/doi.org\/10.4161\/cbt.29452 (2014).","journal-title":"Cancer Biol Ther"},{"key":"40635_CR26","doi-asserted-by":"publisher","unstructured":"Besse, A. et al. Carfilzomib resistance due to ABCB1\/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma. Leukemia, https:\/\/doi.org\/10.1038\/leu.2017.212 (2017).","DOI":"10.1038\/leu.2017.212"},{"key":"40635_CR27","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1124\/jpet.111.187542","volume":"341","author":"SE Verbrugge","year":"2012","unstructured":"Verbrugge, S. E. et al. Inactivating PSMB5 mutations and P-glycoprotein (multidrug resistance-associated protein\/ATP-binding cassette B1) mediate resistance to proteasome inhibitors: ex vivo efficacy of (immuno)proteasome inhibitors in mononuclear blood cells from patients with rheumatoid arthritis. J Pharmacol Exp Ther 341, 174\u2013182, https:\/\/doi.org\/10.1124\/jpet.111.187542 (2012).","journal-title":"J Pharmacol Exp Ther"},{"key":"40635_CR28","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1126\/science.aaf8993","volume":"353","author":"J Schrader","year":"2016","unstructured":"Schrader, J. et al. The inhibition mechanism of human 20S proteasomes enables next-generation inhibitor design. Science 353, 594\u2013598, https:\/\/doi.org\/10.1126\/science.aaf8993 (2016).","journal-title":"Science"},{"key":"40635_CR29","doi-asserted-by":"publisher","first-page":"10403","DOI":"10.1073\/pnas.96.18.10403","volume":"96","author":"L Meng","year":"1999","unstructured":"Meng, L. et al. Epoxomicin, a potent and selective proteasome inhibitor, exhibits in vivo antiinflammatory activity. Proc Natl Acad Sci USA 96, 10403\u201310408 (1999).","journal-title":"Proc Natl Acad Sci USA"},{"key":"40635_CR30","doi-asserted-by":"publisher","first-page":"e29471","DOI":"10.1371\/journal.pone.0029471","volume":"7","author":"J Dahlqvist","year":"2012","unstructured":"Dahlqvist, J., Torma, H., Badhai, J. & Dahl, N. siRNA silencing of proteasome maturation protein (POMP) activates the unfolded protein response and constitutes a model for KLICK genodermatosis. PLoS One 7, e29471, https:\/\/doi.org\/10.1371\/journal.pone.0029471 (2012).","journal-title":"PLoS One"},{"key":"40635_CR31","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nrm2630","volume":"10","author":"S Murata","year":"2009","unstructured":"Murata, S., Yashiroda, H. & Tanaka, K. Molecular mechanisms of proteasome assembly. Nat Rev Mol Cell Biol 10, 104\u2013115, https:\/\/doi.org\/10.1038\/nrm2630 (2009).","journal-title":"Nat Rev Mol Cell Biol"},{"key":"40635_CR32","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.ccr.2012.08.007","volume":"22","author":"D Chauhan","year":"2012","unstructured":"Chauhan, D. et al. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell 22, 345\u2013358, https:\/\/doi.org\/10.1016\/j.ccr.2012.08.007 (2012).","journal-title":"Cancer Cell"},{"key":"40635_CR33","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1007\/s12013-013-9626-4","volume":"67","author":"KC Carmony","year":"2013","unstructured":"Carmony, K. C. & Kim, K. B. Activity-based imaging probes of the proteasome. Cell Biochem Biophys 67, 91\u2013101, https:\/\/doi.org\/10.1007\/s12013-013-9626-4 (2013).","journal-title":"Cell Biochem Biophys"},{"key":"40635_CR34","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1146\/annurev.immunol.15.1.749","volume":"15","author":"U Boehm","year":"1997","unstructured":"Boehm, U., Klamp, T., Groot, M. & Howard, J. C. Cellular responses to interferon-gamma. Annu Rev Immunol 15, 749\u2013795, https:\/\/doi.org\/10.1146\/annurev.immunol.15.1.749 (1997).","journal-title":"Annu Rev Immunol"},{"key":"40635_CR35","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1084\/jem.187.1.97","volume":"187","author":"TA Griffin","year":"1998","unstructured":"Griffin, T. A. et al. Immunoproteasome assembly: cooperative incorporation of interferon gamma (IFN-gamma)-inducible subunits. J Exp Med 187, 97\u2013104 (1998).","journal-title":"J Exp Med"},{"key":"40635_CR36","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1089\/jir.2006.0162","volume":"27","author":"DA Jaitin","year":"2007","unstructured":"Jaitin, D. A. & Schreiber, G. Upregulation of a small subset of genes drives type I interferon-induced antiviral memory. J Interferon Cytokine Res 27, 653\u2013664, https:\/\/doi.org\/10.1089\/jir.2006.0162 (2007).","journal-title":"J Interferon Cytokine Res"},{"key":"40635_CR37","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1016\/j.cell.2013.01.037","volume":"152","author":"JA Nathan","year":"2013","unstructured":"Nathan, J. A. et al. Immuno- and constitutive proteasomes do not differ in their abilities to degrade ubiquitinated proteins. Cell 152, 1184\u20131194, https:\/\/doi.org\/10.1016\/j.cell.2013.01.037 (2013).","journal-title":"Cell"},{"key":"40635_CR38","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1158\/0008-5472.CAN-04-4316","volume":"65","author":"GP Dunn","year":"2005","unstructured":"Dunn, G. P., Sheehan, K. C., Old, L. J. & Schreiber, R. D. IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res 65, 3447\u20133453, https:\/\/doi.org\/10.1158\/0008-5472.CAN-04-4316 (2005).","journal-title":"Cancer Res"},{"key":"40635_CR39","doi-asserted-by":"publisher","first-page":"2609","DOI":"10.1056\/NEJMoa030288","volume":"348","author":"PG Richardson","year":"2003","unstructured":"Richardson, P. G. et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 348, 2609\u20132617, https:\/\/doi.org\/10.1056\/NEJMoa030288 (2003).","journal-title":"N Engl J Med"},{"key":"40635_CR40","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2007-08-104950","volume":"112","author":"R Oerlemans","year":"2008","unstructured":"Oerlemans, R. et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood 112, 2489\u20132499, https:\/\/doi.org\/10.1182\/blood-2007-08-104950 (2008).","journal-title":"Blood"},{"key":"40635_CR41","doi-asserted-by":"publisher","first-page":"77622","DOI":"10.18632\/oncotarget.12731","volume":"7","author":"YX Wu","year":"2016","unstructured":"Wu, Y. X., Yang, J. H. & Saitsu, H. Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance. Oncotarget 7, 77622\u201377634, https:\/\/doi.org\/10.18632\/oncotarget.12731 (2016).","journal-title":"Oncotarget"},{"key":"40635_CR42","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1039\/c3mb70471h","volume":"10","author":"JE Park","year":"2014","unstructured":"Park, J. E. et al. A FRET-based approach for identification of proteasome catalytic subunit composition. Mol Biosyst 10, 196\u2013200, https:\/\/doi.org\/10.1039\/c3mb70471h (2014).","journal-title":"Mol Biosyst"},{"key":"40635_CR43","doi-asserted-by":"publisher","first-page":"9874","DOI":"10.1021\/jacs.6b04207","volume":"138","author":"G de Bruin","year":"2016","unstructured":"de Bruin, G., Xin, B. T., Florea, B. I. & Overkleeft, H. S. Proteasome Subunit Selective Activity-Based Probes Report on Proteasome Core Particle Composition in a Native Polyacrylamide Gel Electrophoresis Fluorescence-Resonance Energy Transfer Assay. J Am Chem Soc 138, 9874\u20139880, https:\/\/doi.org\/10.1021\/jacs.6b04207 (2016).","journal-title":"J Am Chem Soc"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-40635-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-40635-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-40635-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T07:16:50Z","timestamp":1671261410000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-40635-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,11]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["40635"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-40635-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,11]]},"assertion":[{"value":"6 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"4089"}}